Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials

Summary

The hypothesis of atherosclerosis as an inflammatory process has been a leitmotiv in cardiology for the past 20 years, and has now led to the launch of clinical trials aimed at testing whether drugs that primarily target inflammation can reduce cardiovascular events. Inflammation indeed drives all phases of atherosclerosis, from inception, through progression, and ultimately acute thrombotic complications (plaque rupture and probably plaque erosion). Since plaque rupture and erosion cause most acute coronary syndromes, appropriately tuned anti-inflammatory treatments should limit myocardial infarction and cardiovascular death. Beyond interrupting inflammation-related plaque disruption, such treatments might, however, also ameliorate the propensity to thrombosis once the trigger (plaque rupture or erosion) has occurred. Several lines of evidence support this view: experimental data document the role of inflammation in platelet activation, tissue factor-mediated coagulation, hyperfibrinogenaemia, impaired activity of natural anticoagulants (including those expressed by endothelial cells), and reduced fibrinolytic activity. Supporting evidence also derives from the involvement of inflammation in venous thrombosis, a process that commonly occurs in the absence of traditional risk factors for atherosclerosis but is associated with several inflammatory diseases including obesity. Ongoing trials, in addition to evaluating effects on primary outcomes, will afford the opportunity to probe the possibility that anti-inflammatory interventions that yield salutary changes in biomarkers of the thrombotic/fibrinolytic balance also translate into reduction of clinical events.

Keywords

Inflammation - thrombosis - methotrexate - colchicine - interleukin-1 receptor antagonist

• References

• 1 Ramji DP, Davies TS. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev 2015 Epub ahead of print.
• 2 Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-212.
• 3 Bentzon JF. et al. Mechanisms of plaque formation and rupture. Circ Res 2014; 114: 1852-1866.
• 4 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
• 5 Nagareddy P, Smyth SS. Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol 2013; 20: 457-463.
• 6 Andriantsitohaina R. et al. Microparticles as regulators of cardiovascular inflammation. Trends Cardiovasc Med 2012; 22: 88-92.
• 7 Nidorf SM. et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61: 404-410.
• 8 Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014; 35: 1782-1791.
• 9 O’Donoghue ML. et al. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. J Am Med Assoc 2016; 315: 1591-1599.
• 10 Ammirati E. et al. The role of T and B cells in human atherosclerosis and athe-rothrombosis. Clin Exp Immunol 2015; 179: 173-187.
• 11 Libby P. Act local, act global: inflammation and the multiplicity of „;vulnerable” coronary plaques. J Am Coll Cardiol 2005; 45: 1600-1602.
• 12 Hamad OA. et al. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv Exp Med Biol 2012; 946: 185-205.
• 13 Borissoff JI, Joosen IA, Versteylen MO. et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 2013; 33: 2032-2040.
• 14 Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13: 34-45.
• 15 Foley JH, Conway EM. Cross Talk Pathways Between Coagulation and Inflammation. Circ Res 2016; 118: 1392-1408.
• 16 Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. Crit Rev Oncol Hematol 2016; 99: 272-285.
• 17 Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. Semin Thromb Haemost 2007; 33: 588-596.
• 18 de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44: 106-113.
• 19 Franchini M, Mannucci PM. Association between venous and arterial thrombosis: clinical implications. Eur J Intern Med 2012; 23: 333-337.
• 20 Fuchs TA. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885.
• 21 von Bruhl ML. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
• 22 Prandoni P. et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441.
• 23 Poredos P, Jezovnik MK. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol 2007; 26: 306-311.
• 24 Sorensen HT. et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370: 1773-1779.
• 25 Spencer FA. et al. The relationship between unprovoked venous thromboembol-ism, age, and acute myocardial infarction. J Thromb Haemost 2008; 06: 1507-1513.
• 26 Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des 2012; 18: 1478-1493.
• 27 Minno Di MN. et al. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med 2012; 07: 9-13.
• 28 Piazza G, Goldhaber SZ. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 2010; 121: 2146-2150.
• 29 Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-1720.
• 30 Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14: 55-61.
• 31 Margetic S. Inflammation and haemostasis. Biochem Med 2012; 22: 49-62.
• 32 Levi M. et al. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.
• 33 Libby P. et al. Functions of vascular wall cells related to development of transplantation-associated coronary arteriosclerosis. Transplant Proc 1989; 21: 3677-3684.
• 34 O’Brien M. The reciprocal relationship between inflammation and coagulation. Top Companion Anim Med 2012; 27: 46-52.
• 35 Verhamme P, Hoylaerts MF. Haemostasis and inflammation: two of a kind?. Thromb J 2009; 07: 15.
• 36 Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005; 15: 254-259.
• 37 Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 01: 1343-1348.
• 38 Rondina MT. et al. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res 2013; 112: 1506-1519.
• 39 De Caterina R. et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombo-sis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.
• 40 Schonbeck U. et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000; 156: 7-14.
• 41 Mach F. et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromely-sin, and tissue factor. Circulation 1997; 96: 396-399.
• 42 Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 08: 1257-1262.
• 43 Levi M. et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27: 3-9.
• 44 Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012; 34: 43-62.
• 45 Aleman MM. et al. Fibrinogen and red blood cells in venous thrombosis. Thromb Res 2014; 133 (Suppl. 01) S38-40.
• 46 Fatah K. et al. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipopro-teins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
• 47 Fatah K. et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
• 48 Collet JP. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
• 49 Undas A. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196: 551-557.
• 50 Undas A. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
• 51 Undas A, Ariens RA. Fibrin clot structure and function: a role in the patho-physiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
• 52 Ariens RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11 (Suppl. 01) 294-305.
• 53 Brill A. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10: 136-144.
• 54 Savchenko AS. et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J Thromb Haemost 2014; 12: 860-870.
• 55 Warnatsch A. et al. Inflammation. Neutrophil extracellular traps license macro-phages for cytokine production in atherosclerosis. Science 2015; 349: 316-320.
• 56 Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123: 2768-2776.
• 57 Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumato-logic conditions. Eur Heart J 2015; 36: 482-489c.
• 58 Holmqvist ME. et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. J Am Med Assoc 2012; 308: 1350-1356.
• 59 Choi HK. et al. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis 2013; 72: 1182-1187.
• 60 Kim SC. et al. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res 2013; 65: 1600-1607.
• 61 Kim SC. et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med 2015; 128: 539. e7-17.
• 62 Tan VP. et al. Venous and arterial disease in inflammatory bowel disease. J Gas-troenterol Hepatol 2013; 28: 1095-1113.
• 63 Magro F. et al. Venous thrombosis and prothrombotic factors in inflammatory bowel disease. World J Gastroenterol 2014; 20: 4857-4872.
• 64 Zezos P. et al. Inflammatory bowel disease and thromboembolism. World J Gas-troenterol 2014; 20: 13863-13878.
• 65 Cugno M. et al. Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk. PLoS One 2015; 10: e0129456.
• 66 Cunningham M. et al. Are microparticles the missing link between thrombosis and autoimmune diseases? Involvement in selected rheumatologic diseases. Semin Thromb Haemost 2014; 40: 675-681.
• 67 Emmi G, Silvestri E, Squatrito D. et al. Thrombosis in vasculitis: from pathogen-esis to treatment. Thromb J 2015; 13: 15.
• 68 Niccolai E. et al. Microparticles: Bridging the Gap between Autoimmunity and Thrombosis. Semin Thromb Haemost 2015; 41: 413-422.
• 69 Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune diseases: A narrative review with emphasis on primary systemic vasculitides. Vasc Med 2015; 20: 369-376.
• 70 Yusuf HR. et al. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U. S. cohort of commercial insurance enrollees. Thromb Res 2015; 135: 50-57.
• 71 Xiong J. et al. Microvesicles at the crossroads between infection and cardiovascular diseases. J Cardiovasc Pharmacol 2012; 59: 124-132.
• 72 Levi M. et al. Sepsis and thrombosis. Semin Thromb Haemost 2013; 39: 559-566.
• 73 Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J 2016 Epub ahead of print.
• 74 Naci H. et al. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol 2013; 20: 641-657.
• 75 Ridker PM. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
• 76 Ridker PM. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
• 77 Danesh J. et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 2007; 22: 839-869.
• 78 Ridker PM. et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
• 79 Hsia J. et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol 50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57: 1666-1675.
• 80 Glynn RJ. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
• 81 Available at: http://www.gsk.com/en-gb/media/press-releases/2015/gsk-provides-update-on-latitude-timi-60-losmapimod-cardiovascular-study/ Accessed June 4, 2016.
• 82 Ridker PM. et al. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162: 597-605.
• 83 Chen Z. et al. Endothelial dysfunction: the role of sterol regulatory element-binding protein-induced NOD-like receptor family pyrin domain-containing protein 3 inflammasome in atherosclerosis. Curr Opin Lipidol 2014; 25: 339-349.
• 84 de Zoete MR, Palm NW, Zhu S. et al. Inflammasomes. Cold Spring Harb Per-spect Biol 2014; 06: a016287.
• 85 Levy M. et al. Taming the inflammasome. Nat Med 2015; 21: 213-215.
• 86 Duewell P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
• 87 Robbins GR. et al. Inflammasomes and metabolic disorders: old genes in modern diseases. Mol Cell 2014; 54: 297-308.
• 88 Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 07 (Suppl. 01) 332-339.
• 89 Everett BM. et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013; 166: 199-207. e15.
• 90 Available at: https://clinicaltrials.gov/ct2/show/NCT01331837 Accessed June 5, 2016.
• 91 Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 2015; 116: 307-311.
• 92 Angelakopoulou A. et al. Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Eur Heart J 2012; 33: 393-407.
• 93 Sarwar N. et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379: 1205-1213.
• 94 Torre-Amione G. et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-711.
• 95 Varbo A. et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013; 128: 1298-1309.
• 96 Libby P. Fanning the flames: inflammation in cardiovascular diseases. Cardiov-asc Res 2015; 107: 307-309.
• 97 Ridker PM. The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes 2009; 02: 279-285.